1-{[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]acetyl}-5-nitroindoline | 474522-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-{[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]acetyl}-5-nitroindoline
• 英文别名: 2-[6-(2,5-dimethylpyrrol-1-yl)pyridin-2-yl]-1-(5-nitro-2,3-dihydroindol-1-yl)ethanone
• CAS: 474522-19-5
• 化学式: C₂₁H₂₀N₄O₃
• 分子量: 376.415
• InChiKey: UHRFOAWHIJRPGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  [6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]acetic acid 、 5-硝基二氢吲哚 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 18.0h， 生成 1-{[6-(2,5-dimethyl-1H-pyrrol-1-yl)-2-pyridinyl]acetyl}-5-nitroindoline
  参考文献：
  名称：

  [EN] AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA
  [FR] COMPOSES AMIDE

  摘要：

  公开号：

  WO2004039795A3

文献信息

• Amide compounds
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040133008A1

  公开（公告）日：2004-07-08

  A compound of the formula (I) 1 wherein R 1 is hydrogen, lower alkyl, lower alkenyl, halo(lower)alkyl, cyclo(lower)alkyl, lower alkoxy, lower alkylthio, acyl, optionally substituted aryl or NR 3 R 4 ; R 2 is hydrogen; or aryl or heteroaryl, each of which may be substituted; X is direct bond or bivalent residue derived from piperazine; Y is -(A 1 ) n -(A 2 ) m -, wherein n and m are independently 0 or 1); 2 is bivalent residue derived from arene or heteroarene; and 3 is bivalent residue derived from arene or heteroarene, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  化合物的式子为（I）1，其中R1为氢、低级烷基、低级烯基、卤素（低）烷基、环（低）烷基、低级烷氧基、低级烷硫基、酰基、可选取代的芳基或NR3R4；R2为氢；或芳基或杂环芳基，每个可以被取代；X为直接键或由哌嗪衍生的二价残基；Y为-(A1)n-(A2)m-，其中n和m独立地为0或1）；2为由芳烃或杂芳烃衍生的二价残基；3为由芳烃或杂芳烃衍生的二价残基，或其盐。本发明的化合物及其盐抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由高循环Apo B水平引起的疾病或状况的药物。
• Heterocyclic amide compounds as apolipoprotein b inhibitors
  申请人：Takasugi Hisashi

  公开号：US20050038035A1

  公开（公告）日：2005-02-17

  The present invention relates to a compound of the formula (I) wherein R 1 is optionally substituted aryl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A 1 ) m1 -(A 2 ) m2 -; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及一种化合物，其分子式为（I），其中R1为可选取代芳基；R2为可选取代芳基、可选取代杂环芳基、可选取代较低环烷基、可选取代芳氧基、可选取代芳基磺酰基、乙烯基、氨基甲酰基、保护羧基或保护氨基；环A为由可选取代芳基或可选取代杂环芳基衍生的二价残基；X为由环烷烯、萘、不饱和的5或6元杂单环基衍生的二价残基，每种残基均可选取代，以及取代苯基；Y为-(A1)m1-(A2)m2-；Z为直接键或哌嗪，或其盐。本发明的化合物及其盐能抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于高循环Apo B水平引起的疾病或病症的药物。
• BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1383760A1

  公开（公告）日：2004-01-28
• HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1472226A1

  公开（公告）日：2004-11-03
• [EN] AMIDE COMPOUNDS<br/>[FR] COMPOSES BIARYLCARBOXAMIDE COMME INHIBITEURS D'APOLIPOPROTEINE B
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002090347A1

  公开（公告）日：2002-11-14

  The present invention relates to compounds of the formula (I) wherein X1 is wherein R?1, R2 and R10¿ are independently hydrogen or a suitable substituent; R?11 and R12¿ are independently hydrogen or a suitable substituent; R is unsaturated 5 to 6-membered heteromonocyclic group; A is direct bond or -NH-; X2 is monocyclic arylene, unsaturated 5 to 6-membered heteromonocyclic group or cycloalkenylene; Y is bivalent group selected from ethylene, trimethylene and vinylene, wherein CH2 is optionally replaced by NH or O, and CH is optionally replaced by N; and Z is -(CH¿2?)n-, -CO-(CH2)m-, -CH=CH- or -CO-NH-, wherein n is 1, 2 or 3 and m is 1 or 2, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.